60 results about "Arterial dissection" patented technology

The present invention is an apparatus designed to effectuate restoration of normal aortic valvular function where there is aortic valvular regurgitation either primary or secondary to diseases of the aorta such as aortic aneurysm, aortic dissection, rheumatic aortic disease annuloaortic ectasia and etc. is present. The present invention provides an apparatus for repairing aortic annulus composed of (1) a band type inner stabilizer (sometimes ring type inner stabilizer) which is implanted in the true aortic lumen to fix the aortic annular diameter and (2) an outer felt stabilizer which is implanted on the outside surface of aorta to support the inner stabilizer. Furthermore, the present invention provides an apparatus for restoring the sinotubular junction in the ascending aorta which is composed of (1) a ring type inner stabilizer which is implanted in the sinotubular junction in the ascending aorta and (2) an outer felt stabilizer which is implanted on the outside surface of the sinotubular junction to support the inner stabilizer.

Methods and devices for treating an aortic dissection having an entry point downstream of the takeoff of the left subclavian artery. The devices include a catheter that carries an endoluminal implant at a distal region of the catheter. The implant is a self-expanding tubular mesh or strutted stent. A capture sheath holds the stent in a compressed state for percutaneous delivery. The catheter is advanced to position the stent adjacent the entry point of the dissection. The stent is released by withdrawing the capture sheath. The stent expands to engage the intimal lining and press the intima into contact with the outer layers of the aorta and thereby promote healing of the dissection.

The invention discloses a method for preparing a personalized bionic drug eluting coronary stent by using a 3D printing technology and a product. The method for preparing the personalized bionic drug eluting coronary stent comprises the step that according to image data of coronary angiogram, adopting a QCA technique for measuring the diameter of a diseased coronary artery and reconstructing in a three-dimensional manner. According to indexes such as lesion vascular diameter, lesion length and lesion vascular pattern, a personalized coronary stent can be made for each patient in a customized manner and a stent most suitable for the lesion state of a patient can be prepared. The personalized bionic drug eluting coronary stent can be made of degradable poly L-lactic acid (PLLA) or other materials, after 3D printing molding, the surface of the stent can be coated with a polymer with anti-proliferation medicines by using a conventional process, and in-stent restenosis can be reduced (the polymer is prepared by mixing a medicine with PDLLA in a ratio of the medicine to PDLLA being 1:1). The most suitable personalized bionic drug eluting coronary stent can be customized for the patient according to diseased coronary arteries of different states, requirements of different lesions can be met, customization of coronary stents can be achieved, and complications such as vascular injury, thrombus and coronary arterial dissection caused by mismatching of the diameter of the stent and that of the blood vessel can be reduced.

The invention discloses a human body thoracic and abdominal cavity CT image aorta segmentation method based on a GVF Snake model. The method overcomes the shortcomings of the heavy workload and long time consuming of the traditional manual and semi-automatic segmentation, the repeatability of the method is good, and the uncertainty caused by artificial segmentation is prevented. The method includes (1) reading a CT image and performing image preprocessing; (2) performing the initial profile setting of the GVF Snake model on the image obtained after the preprocessing; (3) obtaining the edge image of the image after the preprocessing; (4) obtaining gradient vector flow GVF as the external energy field by the diffusion equation based on the obtained edge image; (5) establishing an internal energy model to maintain the smoothness of the profile; and (6) constructing an energy function E by means of internal energy and external energy, obtaining the minimum value of energy E by means of iteration operation, and the target boundary of the profile can be obtained at the end. The method has important application values in the field of human body thoracic and abdominal cavity aorta interlayer segmentation diagnosis treatment.

The methods and devices disclosed herein pertain to the percutaneous treatment of various forms of aortic dissection by at least partially filling the false lumen of the aortic dissection with a stabilization agent percutaneously and steps to decrease the size of the false lumen using the devices. Fluid maybe aspirated from the false lumen to decrease the volume of the false lumen. And the entrance opening between the true lumen and the false lumen may be sealed with a sealing agent such as a biocompatible adhesive. The medical devices disclosed herein generally comprise an extendable sealing element that is used in conjunction with a catheter to expand the true lumen while reducing the size of the false lumen. The device has the ability to aspirate and / or deliver fluid containing the stabilization agent into the false lumen.

An occlusion device for vascular surgery, suitable for clogging treatments of vascular entry sites and for endovascular interventions such as embolizations of blood vessels, treatment of arteriovenous malformations or small aneurysms, arterial dissections and the like, by releasing in an operation region a quick setting surgical glue or haemostatic fluid, through an outlet mouth of a duct. The device prevents the surgical glue from contacting within the duct a patient's biological fluids, in particular blood, which would close the duct. In the case of clogging treatments of vascular entry sites, a backflow preventing device may be provided, preferably provided by a coupling device between the duct and an introducer sheath by which an outlet mouth is kept in contact to keep in a one-way fluid tight contact against the outer surface of the introducer sheath until an injection pressure P2 is applied to cause release of the surgical glue.

The invention provides a model building method for dissection of aorta, a model and a surgery simulation detection method. The model building method includes acquiring CTA video data of the aorta of apatient; building a three-dimensional model for the dissection of aorta according to the acquired CTA video data; performing 3D printing according to the three-dimensional model to prepare a model for dissection of aorta by utilizing a transparent material having elasticity same as that of blood vessels of the patient; arranging a pressure sensor on the inner side of the wall of the aorta in themodel for dissection of aorta, and arranging a flow sensor at an aorta branch outlet of the model for dissection of aorta. Accordingly, a physician can perform surgery simulation before actual surgeries.

The invention discloses a covered stent for aortic dissection surgery, a conveying device and a use method. The stent comprises a body which is a covered stent body. The stent is a conical stent with the diameter gradually reduced from the cardiac proximal portion to the thoracic aorta distal portion. An exposed portion is arranged on the lower portion of the body of the stent and is not covered. Three balloon dilatation stents are connected to the upper edge of the middle of the body. A protective gasket made from polytetrafluoroethylene is arranged at the near end of the body. The three balloon dilatation stents are provided with three catheters respectively. Each catheter is about 2 m long. The conveying device comprises a conveying sheath, the body of the stent is compressed in the conveying sheath, and the three balloon dilatation stents on the middle section of the body are compressed in the conveying sheath. A conveying sheath system is provided with an apex, and notches are formed in the tip end of the conveying sheath system for the body of the stent and guide wires and the catheters of the three balloon dilatation stents. The invention provides the covered stent for aortic dissection surgery. The stent is used for minimally invasive surgery treatment of Stanford A type aortic dissection with a wound among three branch vessels on the arcus aortae, avoids injuries caused by thoracotomy, and can be directly used for intra-cardiac wound occlusion.

An implantable medical device (30) for treating aortic dissections includes a stent graft part (34) having a bulbous section (48) of greater radial diameter than the radial diameter of first and second sections (60,62) of the stent graft part (34). The bulbous section (48) is able to close off the false lumen (10) of an aortic dissection, thereby to prevent any fluid backflow into the false lumen (10). Radiopaque markers (70) may be provided for orientation and deployment purposes. The device (30) is able to treat chronic dissections and reduce false lumen backflow, which remains otherwise an unresolved issue in the endovascular treatment of false lumen aneurysms.

The methods and devices disclosed herein pertain to the percutaneous treatment of various forms of aortic dissection by at least partially filling the false lumen of the aortic dissection with a stabilization agent percutaneously and steps to decrease the size of the false lumen using the devices. Fluid maybe aspirated from the false lumen to decrease the volume of the false lumen. And the entrance opening between the true lumen and the false lumen may be sealed with a sealing agent such as a biocompatible adhesive. The medical devices disclosed herein generally comprise an extendable sealing element that is used in conjunction with a catheter to expand the true lumen while reducing the size of the false lumen. The device has the ability to aspirate and / or deliver fluid containing the stabilization agent into the false lumen.

The invention discloses an establishing method and application of a mouse aortic dissecting aneurysm model. The establishing method of the mouse aortic dissecting aneurysm model is simple and convenient, the mouse aortic dissecting aneurysm model can be established within a short time, surgical operation is not needed, trauma to experimental mice can be reduced, and high operability is achieved. The occurrence rate of aortic dissecting aneurysm of a modeling group is 90%, the breaking rate of the aortic dissecting aneurysm of the modeling group is 20%, the occurrence rate of the aortic dissecting aneurysm in chests and aortic dissection above chests is 90%, the occurrence rate of the aortic dissecting aneurysm in abdomen is 20%, and the induction success rate is high. The dissection occurrence position of the aortic dissecting aneurysm is similar to that of human beings, so that the mouse aortic dissecting aneurysm model can be used for easily studying the pathomechanism of the aortic dissecting aneurysm of human beings and can be applied to suspicious virulence gene screening and treatment research.

The invention relates to the technical field of biology, in particular to a purpose of an HSP90 inhibitor in preparation of medicine for preventing and treating aortic diseases. The HSP90 inhibitor is used for preparing medicine or a reagent for preventing or treating aortic dissection. The invention also provides a method for screening potential substances for preventing or treating the aortic diseases, and a method for preventing or treating the aortic diseases of mammal. The invention discloses the purpose of the HSP90 inhibitor for specially inhibiting the aortic dissection cracking for the first time, and discloses the close relevancy of the HSP90 expression to the aortic diseases for the first time, so that a novel target point is provided for the large vessel disease prevention and treatment.

Compounds represented by formula (I), prodrugs thereof and salts thereof, and pharmaceutical compositions comprising the same as an active ingredient (wherein each symbol has the meaning as defined in the specification.). Because of having an EDG-1 agonism, the compounds represented by formula (I) are useful in preventing and / or treating peripheral arterial disease such as arteriosclerosis obliterans, thromboangiitis obliterans, Buerger's disease or diabetic neuropathy, sepsis, angiitis, nephritis, pneumonia, stroke, myocardial infarction, edematous state, atherosclerosis, varicosity such as hemorrhoid, anal fissure or fistula ani, dissecting aneurysm of the aorta, angina, DIC, pleuritis, congestive heart failure, multiple organ failure, bedsore, burn, chronic ulcerative colitis, Crohn's disease, heart transplantation, renal transplantation, dermal graft, liver transplantation, osteoporosis, pulmonary fibrosis, interstitial pneumonia, chronic hepatitis, liver cirrhosis, chronic renal failure, or glomerular sclerosis.

The invention provides an establishment method of an animal model for acute Stanford A-type aortic dissection (AD) accompanied with MODS (multiple organ dysfunction syndrome), a use of emodin for preparing a medicine for treating acute Stanford A-type AD accompanied with MODS as well as a viscera protective agent for acute Stanford A-type AD accompanied with MODS. In the invention, an AD surgery method is improved and meanwhile manually controlled hypertension is formed by continuously pumping adrenaline into veins so as to promote expansion of the AD stripping range and accelerate disease progression, thus acute Stanford A-type AD accompanied with MODS can be rapidly formed so as to successfully make the model. The animal model for acute Stanford A-type AD accompanied with MODS creates conditions for further deep research in application foundation and intervention treatment.

The invention discloses a combination-type intra-operative on-demand blocking branched stent-type blood vessel. The stent-type blood vessel is used in open-type operations of replacing aorta arches and branch blood vessels thereof during the aortic dissection treatment. The combination-type intra-operative on-demand blocking branched stent-type blood vessel comprises two or three stent-type blood vessel bodies from the distal end of the aorta arch to the proximal end of the aorta arch, can be suitable for individual structures of three branch blood vessels of the aorta arch of a patient, and improves the matching degrees between the stent-type blood vessel and the three branch blood vessels of the human-body aorta arch. When the stent-type blood vessel is used, dissociative brachiocephalic blood vessels can be avoided or reduced, it is unnecessary to replace the aorta arch and branch blood vessels, anastomotic stomas are reduced, and the extracorporeal circulation time and the unilateral cerebral perfusion time are shortened, so that operative manipulation difficulties and operative wounds are reduced, the operation time is shortened, postoperative complications are reduced, and the mortality rate is reduced.

The invention provides application of naringenin to the preparation of products for preventing and / or treating aortic dissection. The drugs for preventing and / or treating aortic dissection are safe and low-toxic, and high in pharmacological action; the source of raw materials are rich and wide, the price is low, and the raw materials can be obtained from crude products or monomer of naringin through a hydrolysis method, obtained by extracting from medicinal materials containing naringenin, or obtained by synthesis through other chemical methods; the cost is low, the process is simple, and the yield is high; curative effect is definite, and the effective dose is low. The application provides a novel source of drugs for preventing, diagnosing, detecting, protecting, treating and researching aortic dissection diseases, is easy to promote and apply, and can produce huge social benefit and economic benefit within a short time.

The invention relates to a method for detecting small-molecule metabolic markers in the peripheral blood of aortic dissection, and its application. Combined chromatography and mass spectrometry are employed for high-flux large-scale metabonomic analysis of patients with aortic dissection to determine small-molecule metabolic profiling of the peripheral blood of the aortic dissection, and three small-molecule metabolic markers with greatest difference is obtained, wherein the three small-molecule metabolic markers are N1-acetyl-N2-formyl-5-methoxy kynurenine, glycerophosphorylcholine and 2-mercaptohistidine betaine. The invention provides a simple, low-harm and cheap method for screening and diagnosis of aortic dissection, and effective reference bases can be provided for diagnosis of clinical patients and assessment of the treatment efficacy of drugs.

The invention relates to the technical field of medical instruments, in particular to an endovascular repair graft for treating the aortic dissection false lumen. The endovascular repair graft is composed of an occluding part and a conveying device, wherein the body of the occluding part is of a cylinder structure formed by knitting wire mesh, and the body is covered with membranes, so that the occluding part forms a closed cavity. The endovascular repair graft can be stably fixed to the dissection false lumen and effectively occlude slits to cut off false lumen blood flow. Different from an existing occluder repair device which is placed in the aorta to precisely cover a slit, the occluding part is a closed stent graft and completely covers multiple or even all slits; meanwhile, as both ends, in the axial direction, of the occluding part are covered with the membranes, the occluding part is a closed cylinder, the shape and mechanical properties are strictly suitable for the false lumen, the occluding part can basically or even completely fill the false lumen, it is more difficult for blood to flow in or flow out, the false lumen blood flow is cut off, and thrombosis in the false lumen is accelerated.

The invention discloses application of histone methyltransferase EZH2 to preparation of a medicinal preparation for preventing or treating aortic diseases. The invention confirms that the EZH2 can effectively inhibit autophagy of vascular smooth muscle cells and promote the survival of smooth muscle cells; a novel target spot and strategy are provided for effective treatment of aortic dissection and other aortic diseases with reduction of the vascular smooth muscle cells as the basis of cytology, and a basic is provided for the development of a novel medicament for treating diseases of the type.

The invention belongs to the fields of gene functions and applications, and specifically discloses an application of an FKBP11 gene in prevention and treatment of aortic dissection. In-vitro cell experiments show that vascular endothelial cell SiRNA-mediated FKBP11 gene silencing can inhibit activation of an NF-kB signal pathway, the expression of a proinflammatory cytokine is decreased, and migration of macrophage to an aortic middle layer is inhibited, so that the degradation of a middle-layer substrate is inhibited, and results show that the FKBP11 inhibitor can prevent and treat occurrenceof aortic dissection, and provides theoretical basis and clinical basis for new targets and new strategies for prevention, relieving and / or treatment of aortic dissection.

Endoluminal prosthetic devices having fluid-absorbable compositions for repair of vascular tissue defects, such as an aneurysm or dissection, are disclosed herein. A prosthesis for repairing an opening or cavity within a target vessel region configured in accordance herewith includes a tubular body sized to substantially cover the opening or cavity, and having channels formed in a wall thereof. The channels can include a fluid-absorbable composition deposited therein and which is configured to absorb fluid (e.g., blood) and swell within the channels, thereby providing radial expansion of the tubular body in situ.

The invention relates to tetratype collagen serving as a specific molecular target spot in targeted diagnosis and / or treatment aortic interlayer / aneurysm. A COLIV targeted peptide fragment and a derivative thereof are synthesized autonomously, and occurrence of aortic aneurysm / interlayer is monitored at an early stage by monitoring activation of endothelial cells. The monitoring mode refers to one or multiple of ultrasonic detection, MRI detection, CTA detection and fluorescent imaging detection. In addition, the COLIV targeted peptide fragment can serve as a molecule target spot of a targeted drug delivery system, and higher blood drug concentration and less toxic and side effect at a disease position are guaranteed. Drug is drug for administration through gastrointestinal tract, drug for administration through intravenous injection and drug for administration through subcutaneous embedment, and the drug for administration through subcutaneous embedment preferably.

The invention discloses a device and method for detecting biomechanical properties of aortic dissection lesion blood vessels. The biomechanical property of the diseased blood vessel is detected by using the detection device with two tension handles; when the biomechanical properties of the aortic dissection lesion blood vessels are detected, the bilateral tensile strain, the corresponding stress and the cutting stress of the penetrating suture on the lesion blood vessel wall material due to traction are tested. Through the testing of the bilateral tensile strain, the corresponding stress and the cutting stress generated by the penetrating suture on the vascular wall material of the lesion due to traction for the lesion blood vessel wall, the device achieved the detecting and recording of the biomechanical properties of walls of the aortic dissection lesion blood vessels and provides accurate and effective guidance data for doctors; therefore, the accurate implementation parameters areprovided for the operation process of the aortic canal wall with the dissection lesion, and the operation risk is greatly reduced.

Medical methods and devices for treating aortic dissections. A catheter-based cutting device permits cutting a septum of acute or chronic aortic dissections, in a retrograde manner. The catheter includes a base section having a central lumen therethrough, two flexible arms extending from a distal end thereof, where each arm has a channel therethrough for a passage of a guide wire. With distal ends of the two flexible arms separated, the two arms form a Y-shape with the base section. With distal ends of the two flexible arms together, the two arms have a longitudinal profile, about a periphery thereof, identical to a longitudinal profile of the base section. A non-mechanically actuated cutting component resides between the two arms in a vicinity of the distal end of the base section. The cutting component faces distally outward between the two arms with the distal ends of the two flexible arms separated.

The invention provides an aorta covered stent. The aorta covered stent comprises a main stent, the main stent comprises a main stent body, the main stent body is provided with at least one concave part, a main stent membrane covers the main stent body, and the main stent membrane of the concave part is provided with at least one through hole for a branch arterial stent to stretch into the main stent. The aorta covered stent can be used for treating aortic aneurysm or aortic dissection, internal hemorrhage can be effectively reduced, branch blood flow clogging can be effectively prevented, andthe operation is also convenient.

The invention discloses diagnosis and treatment application of mononuclear / phagocyte cells to aortic injuries. Particularly, aortic dissection (AD) occurs along with infiltration of mononuclear / phagocyte cells at aortic injury parts, so that aortic dissection (AD) related diseases (such as vascular tear, vascular wall thickening, thrombi formed between the tunica media and the adventitia and elastic fiber breakage) can be diagnosed according to infiltration conditions of the mononuclear / phagocyte cells. In addition, the invention further discloses a fact that mononuclear / phagocyte cell knockout can remarkably prevent and / or treat aortic dissection (AD) related diseases and discloses a mononuclear / phagocyte cell inhibitor for remarkable prevention and / or treatment of aortic dissection (AD)related diseases.

The invention discloses a group of biomarkers for assessing the aortic dissection risks and application of the biomarkers. The biomarkers can be one or a combination of several of gene mutation sitesin Table 1. The invention further provides application of the gene mutation sites to preparation of detection products for detecting or assessing the aortic dissection disease. The invention finds 44aortic dissection susceptible mutation sites and studies application prospects thereof in early prediction of aortic dissection; aortic dissection-related gene sites provided by the invention can be used as early biomarkers for the aortic dissection; a new direction is provided for further studying the genetic molecular mechanism of the aortic dissection and exploring medicine targets for early prevention and treatment of the aortic dissection.

The invention requests to protect the application of the asparagine endopeptidase inhibitor RR-11aanalog in preparation of the medicine for treating the aortic dissection, it is found through experiments that asparagine endopeptidase serves as a target spot for occurrence of the aortic dissection, and the RR-11aanalog has the effect of treating the aortic dissection and has great clinical significance in further development of related treatment medicine.